id,indicator_code,spatial_dim_type,iso_code,time_dim_type,region_code,region,dim1type,year,dim1,dim2type,dim2,dim3type,dim3,data_source_dim_type,data_source_dim,value,numeric_value,low,high,comments,date,time_dimension_value,time_dimension_begin,time_dimension_end,country,indicator_name,language,title
9378381,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5106251,GASPRSCRO,COUNTRY,UGA,YEAR,AFR,Africa,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Uganda,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7770282,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4552466,GASPRSCRO,COUNTRY,ISL,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Iceland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5289709,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3596163,GASPRSCRO,COUNTRY,ZAF,YEAR,AFR,Africa,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,South Africa,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8739488,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4603229,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0.94,0.9434,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6414475,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9745708,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
179317,GASPRSCRO,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Pakistan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5965069,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8422598,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5965093,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4647511,GASPRSCRO,COUNTRY,BLR,YEAR,EUR,Europe,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Belarus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10151363,GASPRSCRO,COUNTRY,PAN,YEAR,AMR,Americas,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Panama,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6992077,GASPRSCRO,COUNTRY,KHM,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Cambodia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7745392,GASPRSCRO,COUNTRY,CHN,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,15.2,15.2,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,China,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4858754,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
198556,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2014,NA,NA,NA,NA,NA,NA,NA,5.56,5.55556,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8505186,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7625029,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2012,NA,NA,NA,NA,NA,NA,NA,0.4,0.40107,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6104831,GASPRSCRO,COUNTRY,DOM,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Dominican Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6662189,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,1.82,1.81818,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10043775,GASPRSCRO,COUNTRY,PNG,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Papua New Guinea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2462218,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2481333,GASPRSCRO,COUNTRY,CHE,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0.7,0.7,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Switzerland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6003321,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6535235,GASPRSCRO,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Morocco,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4356634,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,1.04,1.04167,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7447773,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8625776,GASPRSCRO,COUNTRY,EST,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Estonia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2335381,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2969264,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9473888,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9416767,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0.48,0.48031,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5429326,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2014,NA,NA,NA,NA,NA,NA,NA,21.04,21.0356,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6795636,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5365854,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7030108,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8650759,GASPRSCRO,COUNTRY,CZE,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Czechia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
674265,GASPRSCRO,COUNTRY,SLV,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,El Salvador,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6066462,GASPRSCRO,COUNTRY,CUB,YEAR,AMR,Americas,NA,2019,NA,NA,NA,NA,NA,NA,NA,6.9,6.9,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Cuba,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2797808,GASPRSCRO,COUNTRY,ZWE,YEAR,AFR,Africa,NA,2011,NA,NA,NA,NA,NA,NA,NA,12.3,12.3,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Zimbabwe,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9246849,GASPRSCRO,COUNTRY,EST,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Estonia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7776604,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7523536,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3570861,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1136576,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1367449,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
286903,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2937918,GASPRSCRO,COUNTRY,CUB,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Cuba,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6288210,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8689435,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2017,NA,NA,NA,NA,NA,NA,NA,0.2,0.19759,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3007737,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,3.09,3.09079,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6871240,GASPRSCRO,COUNTRY,CHE,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,1.82,1.81818,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Switzerland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1255708,GASPRSCRO,COUNTRY,DOM,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Dominican Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2138867,GASPRSCRO,COUNTRY,ROU,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Romania,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2227717,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2013,NA,NA,NA,NA,NA,NA,NA,0.4,0.40323,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1937153,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1129870,GASPRSCRO,COUNTRY,CHN,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,36.94,36.93957,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,China,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4262197,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7992299,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5346755,GASPRSCRO,COUNTRY,ISL,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Iceland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5775472,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5202347,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3875688,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3875725,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1272771,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1747653,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5670094,GASPRSCRO,COUNTRY,CIV,YEAR,AFR,Africa,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Cote d'Ivoire,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5902480,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9898759,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,2.13,2.12766,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3172019,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6219128,GASPRSCRO,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Oman,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6719797,GASPRSCRO,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Pakistan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8651620,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8822297,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1374466,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2012667,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6118181,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7024618,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
167208,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2355091,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3964214,GASPRSCRO,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Oman,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10126945,GASPRSCRO,COUNTRY,BLR,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Belarus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3311583,GASPRSCRO,COUNTRY,BRN,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,0.51,0.50505,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Brunei Darussalam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8911503,GASPRSCRO,COUNTRY,PAN,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Panama,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7302891,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1406216,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,29.27,29.26829,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10063040,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7752251,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4464688,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
34080,GASPRSCRO,COUNTRY,EST,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Estonia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1298357,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4123286,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9512382,GASPRSCRO,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,NA,2019,NA,NA,NA,NA,NA,NA,NA,5.0,5,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Saudi Arabia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
573056,GASPRSCRO,COUNTRY,MNG,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,19.13,19.13043,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Mongolia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9696013,GASPRSCRO,COUNTRY,ROU,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Romania,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7176515,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,0.03,0.03168,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7385343,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1773397,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4231150,GASPRSCRO,COUNTRY,COL,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Colombia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
883267,GASPRSCRO,COUNTRY,EST,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Estonia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3387430,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,1.83,1.83486,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8315848,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3558543,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2894293,GASPRSCRO,COUNTRY,VNM,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,1.33,1.33333,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Viet Nam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5751472,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1219087,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9083048,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2539080,GASPRSCRO,COUNTRY,BRA,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Brazil,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5075915,GASPRSCRO,COUNTRY,GTM,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Guatemala,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3964958,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0.5,0.5,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1279642,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,25,25,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7106770,GASPRSCRO,COUNTRY,DOM,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Dominican Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9626539,GASPRSCRO,COUNTRY,CYP,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Cyprus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2671599,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2621713,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9620486,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9209547,GASPRSCRO,COUNTRY,MNG,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,30.67,30.66667,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Mongolia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9910983,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2011,NA,NA,NA,NA,NA,NA,NA,0.38,0.38412,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4974579,GASPRSCRO,COUNTRY,CUB,YEAR,AMR,Americas,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Cuba,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6156795,GASPRSCRO,COUNTRY,ZMB,YEAR,AFR,Africa,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Zambia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9487514,GASPRSCRO,COUNTRY,PER,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Peru,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8133569,GASPRSCRO,COUNTRY,VNM,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Viet Nam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4968605,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,0.01,0.01,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8911958,GASPRSCRO,COUNTRY,BRN,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,1.02,1.01695,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Brunei Darussalam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4840623,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9443456,GASPRSCRO,COUNTRY,BLZ,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,12.5,12.5,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belize,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3901748,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,3.51,3.50548,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7771895,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3699170,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
535833,GASPRSCRO,COUNTRY,MYS,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,10,10,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Malaysia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2006818,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5902283,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,1.1,1.1,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6523660,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5556399,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,4.04,4.0404,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7303725,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7860659,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0.28,0.28419,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6993537,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2723516,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,5.04,5.04202,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9348615,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9601828,GASPRSCRO,COUNTRY,CIV,YEAR,AFR,Africa,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cote d'Ivoire,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4642083,GASPRSCRO,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bahrain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4879203,GASPRSCRO,COUNTRY,MUS,YEAR,AFR,Africa,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Mauritius,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
294965,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,4.76,4.7619,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8468558,GASPRSCRO,COUNTRY,ECU,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Ecuador,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9328698,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8505489,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5619161,GASPRSCRO,COUNTRY,BRN,YEAR,WPR,Western Pacific,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Brunei Darussalam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2551571,GASPRSCRO,COUNTRY,HRV,YEAR,EUR,Europe,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Croatia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6359215,GASPRSCRO,COUNTRY,LUX,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Luxembourg,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4891967,GASPRSCRO,COUNTRY,MOZ,YEAR,AFR,Africa,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Mozambique,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1988563,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,3.7,3.7,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7734198,GASPRSCRO,COUNTRY,FIN,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Finland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6567703,GASPRSCRO,COUNTRY,PER,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Peru,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9020677,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5883720,GASPRSCRO,COUNTRY,CHE,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Switzerland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6745480,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5095543,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1906456,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3983937,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
978856,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2982876,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0.05,0.05046,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6447141,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,3.25,3.25177,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6802761,GASPRSCRO,COUNTRY,IDN,YEAR,SEAR,South-East Asia,NA,2016,NA,NA,NA,NA,NA,NA,NA,80,80,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Indonesia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8646298,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2083118,GASPRSCRO,COUNTRY,KHM,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cambodia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4930292,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4956536,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6765427,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3876197,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7804133,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4950200,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8747814,GASPRSCRO,COUNTRY,CHN,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,11.67,11.66893,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,China,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5828072,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,20.35,20.34739,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
839651,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7133207,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0.99,0.9901,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7493793,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7728174,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10171379,GASPRSCRO,COUNTRY,LAO,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Lao People's Democratic Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3446084,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,0.1,0.1,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1544,GASPRSCRO,COUNTRY,BLR,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Belarus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
42932,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3958896,GASPRSCRO,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Pakistan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
171337,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,0.04,0.03829,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
190889,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1261412,GASPRSCRO,COUNTRY,ISL,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Iceland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
254490,GASPRSCRO,COUNTRY,MWI,YEAR,AFR,Africa,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malawi,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
276522,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
279308,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
322735,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
333582,GASPRSCRO,COUNTRY,MNG,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,0.78,0.77519,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Mongolia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
73278,GASPRSCRO,COUNTRY,FJI,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Fiji,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
387863,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0.33,0.33374,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
405128,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
417731,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8722210,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
435780,GASPRSCRO,COUNTRY,MMR,YEAR,SEAR,South-East Asia,NA,2011,NA,NA,NA,NA,NA,NA,NA,12.5,12.5,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Myanmar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
456008,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9272846,GASPRSCRO,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Pakistan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
488121,GASPRSCRO,COUNTRY,COL,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Colombia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9209905,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1818642,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8165745,GASPRSCRO,COUNTRY,HRV,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Croatia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
629098,GASPRSCRO,COUNTRY,CZE,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Czechia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
635402,GASPRSCRO,COUNTRY,CRI,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Costa Rica,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
641454,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7474744,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2983713,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9071062,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9323303,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1080743,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7625850,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
922139,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7335102,GASPRSCRO,COUNTRY,VEN,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
584504,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3857746,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
587000,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
967430,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,2.2,2.2,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9436952,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
209812,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2010,NA,NA,NA,NA,NA,NA,NA,2.21,2.20994,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
462307,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
568708,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
799174,GASPRSCRO,COUNTRY,BOL,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,80,80,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Bolivia (Plurinational State of),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1133801,GASPRSCRO,COUNTRY,ZAF,YEAR,AFR,Africa,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,South Africa,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6232983,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4459435,GASPRSCRO,COUNTRY,UKR,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ukraine,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9734956,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1275572,GASPRSCRO,COUNTRY,CYP,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Cyprus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
727700,GASPRSCRO,COUNTRY,CYP,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Cyprus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
747408,GASPRSCRO,COUNTRY,RUS,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Russian Federation,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1448981,GASPRSCRO,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,NA,2018,NA,NA,NA,NA,NA,NA,NA,3.13,3.125,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Saudi Arabia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
563375,GASPRSCRO,COUNTRY,CIV,YEAR,AFR,Africa,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Cote d'Ivoire,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1454995,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
645891,GASPRSCRO,COUNTRY,UGA,YEAR,AFR,Africa,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Uganda,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7975249,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2165890,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1503616,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
126075,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
759519,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,7.34,7.34007,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
791880,GASPRSCRO,COUNTRY,KGZ,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Kyrgyzstan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
837935,GASPRSCRO,COUNTRY,LAO,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,1.56,1.5625,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Lao People's Democratic Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
418325,GASPRSCRO,COUNTRY,CIV,YEAR,AFR,Africa,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Cote d'Ivoire,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
936965,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1195134,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1221687,GASPRSCRO,COUNTRY,CYP,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Cyprus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1275838,GASPRSCRO,COUNTRY,MDG,YEAR,AFR,Africa,NA,2017,NA,NA,NA,NA,NA,NA,NA,2.5,2.5,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Madagascar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1452232,GASPRSCRO,COUNTRY,SLV,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,El Salvador,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1889291,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1921312,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1941599,GASPRSCRO,COUNTRY,CUB,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Cuba,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
987862,GASPRSCRO,COUNTRY,PER,YEAR,AMR,Americas,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Peru,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1040115,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
387792,GASPRSCRO,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,NA,2017,NA,NA,NA,NA,NA,NA,NA,5.88,5.88235,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Arab Emirates,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
917220,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2174615,GASPRSCRO,COUNTRY,CHN,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,12.05,12.05053,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,China,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
796419,GASPRSCRO,COUNTRY,VNM,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,11.9,11.90476,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Viet Nam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2175857,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1493242,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1578290,GASPRSCRO,COUNTRY,CUB,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Cuba,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1628687,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,3.48,3.48449,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1668797,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1693658,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0.27,0.272,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1249362,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2446228,GASPRSCRO,COUNTRY,CYP,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cyprus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2471343,GASPRSCRO,COUNTRY,MMR,YEAR,SEAR,South-East Asia,NA,2016,NA,NA,NA,NA,NA,NA,NA,100,100,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Myanmar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2505942,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2017,NA,NA,NA,NA,NA,NA,NA,0.48,0.47782,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
942448,GASPRSCRO,COUNTRY,MYS,YEAR,WPR,Western Pacific,NA,2020,NA,NA,NA,NA,NA,NA,NA,6.8,6.8,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Malaysia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2541905,GASPRSCRO,COUNTRY,RUS,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Russian Federation,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2548826,GASPRSCRO,COUNTRY,IDN,YEAR,SEAR,South-East Asia,NA,2014,NA,NA,NA,NA,NA,NA,NA,33.33,33.33333,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Indonesia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1851647,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,0.14,0.13744,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2630535,GASPRSCRO,COUNTRY,SLV,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,El Salvador,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1568423,GASPRSCRO,COUNTRY,COL,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Colombia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1421375,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2763785,GASPRSCRO,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Tunisia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1088950,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1802541,GASPRSCRO,COUNTRY,PAN,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Panama,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1465492,GASPRSCRO,COUNTRY,BRA,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Brazil,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2243985,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2016,NA,NA,NA,NA,NA,NA,NA,8,8,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3000577,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3003311,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2012,NA,NA,NA,NA,NA,NA,NA,0.54,0.53908,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1020197,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0.12,0.12422,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1585374,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,8.2,8.19672,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3043107,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3047507,GASPRSCRO,COUNTRY,ZAF,YEAR,AFR,Africa,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,South Africa,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3079472,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1587494,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3091661,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3100613,GASPRSCRO,COUNTRY,ISL,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Iceland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2337841,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,1.71,1.709,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3125880,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3129226,GASPRSCRO,COUNTRY,PAN,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Panama,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3132109,GASPRSCRO,COUNTRY,MYS,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Malaysia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2122445,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3170107,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,2.83,2.83019,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3206458,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3250749,GASPRSCRO,COUNTRY,MUS,YEAR,AFR,Africa,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Mauritius,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3282824,GASPRSCRO,COUNTRY,FIN,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Finland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2231604,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,5.53,5.5336,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3313304,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,0.44,0.4386,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3345490,GASPRSCRO,COUNTRY,PER,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Peru,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2390330,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3392550,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2018,NA,NA,NA,NA,NA,NA,NA,0.46,0.45872,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3449179,GASPRSCRO,COUNTRY,VNM,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,6.09,6.09137,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Viet Nam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1765200,GASPRSCRO,COUNTRY,BLR,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Belarus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3549688,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,0.89,0.8881,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2936681,GASPRSCRO,COUNTRY,LUX,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Luxembourg,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2528637,GASPRSCRO,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Pakistan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3574325,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2660788,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,6.48,6.48148,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1954149,GASPRSCRO,COUNTRY,UKR,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Ukraine,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3643620,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3652692,GASPRSCRO,COUNTRY,BFA,YEAR,AFR,Africa,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Burkina Faso,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1965066,GASPRSCRO,COUNTRY,ECU,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Ecuador,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3689187,GASPRSCRO,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Oman,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3733465,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3808514,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2014,NA,NA,NA,NA,NA,NA,NA,8.75,8.75,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3840654,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2014,NA,NA,NA,NA,NA,NA,NA,3.3,3.3033,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3852227,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3852774,GASPRSCRO,COUNTRY,LAO,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Lao People's Democratic Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2251920,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3917837,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3927911,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3091510,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3973088,GASPRSCRO,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Morocco,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1978653,GASPRSCRO,COUNTRY,CUB,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Cuba,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4016647,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,1.5,1.5,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4038175,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,8.33,8.33333,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4100491,GASPRSCRO,COUNTRY,CZE,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Czechia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3101061,GASPRSCRO,COUNTRY,MMR,YEAR,SEAR,South-East Asia,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Myanmar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2175697,GASPRSCRO,COUNTRY,IDN,YEAR,SEAR,South-East Asia,NA,2011,NA,NA,NA,NA,NA,NA,NA,16.67,16.66667,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Indonesia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4175431,GASPRSCRO,COUNTRY,URY,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Uruguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2389789,GASPRSCRO,COUNTRY,CYP,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Cyprus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4284025,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4298345,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,1.4,1.4,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4328775,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,25.08,25.07645,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4329397,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1084677,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
1460468,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4441819,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4512814,GASPRSCRO,COUNTRY,MDG,YEAR,AFR,Africa,NA,2019,NA,NA,NA,NA,NA,NA,NA,2.8,2.8,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Madagascar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4563084,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2624026,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2014,NA,NA,NA,NA,NA,NA,NA,0.59,0.59256,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4586571,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3004498,GASPRSCRO,COUNTRY,CHN,YEAR,WPR,Western Pacific,NA,2012,NA,NA,NA,NA,NA,NA,NA,12.78,12.78317,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,China,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4628331,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,1.76,1.76289,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4646464,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3031575,GASPRSCRO,COUNTRY,VEN,YEAR,AMR,Americas,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4742188,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0.6,0.6,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3289481,GASPRSCRO,COUNTRY,SLV,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,El Salvador,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4763204,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,0.27,0.26636,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4794851,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0.27,0.27298,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4798581,GASPRSCRO,COUNTRY,EST,YEAR,EUR,Europe,NA,2019,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2019,2019-01-01T00:00:00+01:00,2019-12-31T00:00:00+01:00,Estonia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4895995,GASPRSCRO,COUNTRY,NIC,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Nicaragua,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4934206,GASPRSCRO,COUNTRY,MNG,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,0.23,0.22523,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Mongolia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3512182,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2898404,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4991177,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2010,NA,NA,NA,NA,NA,NA,NA,19.86,19.86111,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4991964,GASPRSCRO,COUNTRY,ISL,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Iceland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3638526,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3879733,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,27.45,27.45098,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5043040,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3136779,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5115970,GASPRSCRO,COUNTRY,IDN,YEAR,SEAR,South-East Asia,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Indonesia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3390538,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2020,NA,NA,NA,NA,NA,NA,NA,1.0,1,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2891852,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4990057,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2018,NA,NA,NA,NA,NA,NA,NA,3.13,3.125,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5226393,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,0.15,0.14613,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3567278,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2011,NA,NA,NA,NA,NA,NA,NA,9.43,9.43396,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3573588,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5318528,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5337575,GASPRSCRO,COUNTRY,CHL,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Chile,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5381999,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5389195,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3592083,GASPRSCRO,COUNTRY,MNG,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,1.06,1.06383,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Mongolia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5555060,GASPRSCRO,COUNTRY,UGA,YEAR,AFR,Africa,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0.003,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uganda,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4612190,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4729500,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5665633,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
2648117,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5668066,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5699740,GASPRSCRO,COUNTRY,HRV,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Croatia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5724918,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5743718,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2012,NA,NA,NA,NA,NA,NA,NA,0.3,0.29674,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5774062,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4989589,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5862315,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5873491,GASPRSCRO,COUNTRY,ISL,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Iceland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5901017,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6052269,GASPRSCRO,COUNTRY,CHN,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,55.79,55.79399,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,China,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6101655,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6127066,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4760963,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,21.22,21.22371,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6221925,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3954238,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,6.52,6.52174,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6278169,GASPRSCRO,COUNTRY,FJI,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Fiji,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6290158,GASPRSCRO,COUNTRY,MNG,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,23.91,23.91304,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Mongolia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6290370,GASPRSCRO,COUNTRY,TON,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,25,25,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Tonga,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6296384,GASPRSCRO,COUNTRY,PAN,YEAR,AMR,Americas,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Panama,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4133748,GASPRSCRO,COUNTRY,ZAF,YEAR,AFR,Africa,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,South Africa,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6335528,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2011,NA,NA,NA,NA,NA,NA,NA,2.46,2.45902,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4137279,GASPRSCRO,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United Arab Emirates,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6388869,GASPRSCRO,COUNTRY,CIV,YEAR,AFR,Africa,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Cote d'Ivoire,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4915273,GASPRSCRO,COUNTRY,CIV,YEAR,AFR,Africa,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Cote d'Ivoire,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6426903,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6432751,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4259287,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4581115,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6508683,GASPRSCRO,COUNTRY,CIV,YEAR,AFR,Africa,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Cote d'Ivoire,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6540085,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5070529,GASPRSCRO,COUNTRY,VEN,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6559336,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,1.25,1.25,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
3999431,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6676957,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2015,NA,NA,NA,NA,NA,NA,NA,2.9,2.90456,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6734297,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2014,NA,NA,NA,NA,NA,NA,NA,0.23,0.23095,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6747896,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6767441,GASPRSCRO,COUNTRY,VEN,YEAR,AMR,Americas,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Venezuela (Bolivarian Republic of),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6804941,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5137903,GASPRSCRO,COUNTRY,PER,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Peru,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4997283,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6895857,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6911682,GASPRSCRO,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,NA,2014,NA,NA,NA,NA,NA,NA,NA,4.88,4.87805,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Pakistan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6921491,GASPRSCRO,COUNTRY,NZL,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,0.28,0.27701,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,New Zealand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5274376,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6972202,GASPRSCRO,COUNTRY,BLR,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Belarus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5317263,GASPRSCRO,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Bahrain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5020393,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7074092,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7091373,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,1.25,1.25,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7092852,GASPRSCRO,COUNTRY,HRV,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Croatia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4372027,GASPRSCRO,COUNTRY,KHM,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Cambodia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7241828,GASPRSCRO,COUNTRY,DOM,YEAR,AMR,Americas,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Dominican Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
4411279,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7332907,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7374967,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7428206,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7437569,GASPRSCRO,COUNTRY,SVN,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Slovenia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7534695,GASPRSCRO,COUNTRY,HRV,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Croatia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7540162,GASPRSCRO,COUNTRY,BRN,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0.26,0.25707,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Brunei Darussalam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7554510,GASPRSCRO,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Saudi Arabia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5212235,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7665562,GASPRSCRO,COUNTRY,UKR,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ukraine,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7685780,GASPRSCRO,COUNTRY,ZAF,YEAR,AFR,Africa,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,South Africa,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7713180,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,0.07,0.06662,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7767052,GASPRSCRO,COUNTRY,DOM,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Dominican Republic,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7773071,GASPRSCRO,COUNTRY,RUS,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Russian Federation,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6983282,GASPRSCRO,COUNTRY,CZE,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Czechia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7804966,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7868925,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7884259,GASPRSCRO,COUNTRY,MDG,YEAR,AFR,Africa,NA,2016,NA,NA,NA,NA,NA,NA,NA,2.86,2.85714,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Madagascar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7057725,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,19.08,19.07514,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7935166,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6952548,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5540231,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5584046,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8023264,GASPRSCRO,COUNTRY,UGA,YEAR,AFR,Africa,NA,2009,NA,NA,NA,NA,NA,NA,NA,0.68,0.67568,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Uganda,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5630568,GASPRSCRO,COUNTRY,MWI,YEAR,AFR,Africa,NA,2016,NA,NA,NA,NA,NA,NA,NA,92.01,92.00969,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Malawi,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8033402,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5667312,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8074075,GASPRSCRO,COUNTRY,MYS,YEAR,WPR,Western Pacific,NA,2018,NA,NA,NA,NA,NA,NA,NA,2.35,2.35294,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Malaysia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8093750,GASPRSCRO,COUNTRY,CHN,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,21.35,21.34915,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,China,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8106381,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8111759,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
5790938,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6173928,GASPRSCRO,COUNTRY,CUB,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Cuba,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8231532,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6214667,GASPRSCRO,COUNTRY,HUN,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Hungary,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6652696,GASPRSCRO,COUNTRY,RUS,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Russian Federation,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6240929,GASPRSCRO,COUNTRY,ARG,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,0.15,0.14728,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Argentina,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6329644,GASPRSCRO,COUNTRY,BLR,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Belarus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8307536,GASPRSCRO,COUNTRY,VNM,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,2.27,2.27273,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Viet Nam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8364128,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6838360,GASPRSCRO,COUNTRY,KEN,YEAR,AFR,Africa,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Kenya,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8469545,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8476361,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6375298,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8510769,GASPRSCRO,COUNTRY,CAN,YEAR,AMR,Americas,NA,2011,NA,NA,NA,NA,NA,NA,NA,6.19,6.19048,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Canada,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8527236,GASPRSCRO,COUNTRY,UKR,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Ukraine,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8564091,GASPRSCRO,COUNTRY,VNM,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Viet Nam,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8609611,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,21.99,21.99488,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8656512,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8710667,GASPRSCRO,COUNTRY,COL,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Colombia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8724291,GASPRSCRO,COUNTRY,COL,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Colombia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6420031,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,5.17,5.17241,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8814681,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8818437,GASPRSCRO,COUNTRY,DEU,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Germany,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6887788,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8914125,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8989787,GASPRSCRO,COUNTRY,FRA,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,France,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6462308,GASPRSCRO,COUNTRY,COL,YEAR,AMR,Americas,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Colombia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6494977,GASPRSCRO,COUNTRY,BLR,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Belarus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7330426,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9049953,GASPRSCRO,COUNTRY,SVK,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Slovakia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9053660,GASPRSCRO,COUNTRY,NLD,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Netherlands (Kingdom of the),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9088224,GASPRSCRO,COUNTRY,POL,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Poland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9147972,GASPRSCRO,COUNTRY,LUX,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Luxembourg,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9167799,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7343690,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
6550000,GASPRSCRO,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,NA,2020,NA,NA,NA,NA,NA,NA,NA,1.7,1.7,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Bahrain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9199825,GASPRSCRO,COUNTRY,PRT,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Portugal,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7665024,GASPRSCRO,COUNTRY,ECU,YEAR,AMR,Americas,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ecuador,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9326627,GASPRSCRO,COUNTRY,KHM,YEAR,WPR,Western Pacific,NA,2009,NA,NA,NA,NA,NA,NA,NA,3.95,3.94737,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Cambodia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7224639,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9338555,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9357552,GASPRSCRO,COUNTRY,ZAF,YEAR,AFR,Africa,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,South Africa,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9389132,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9434761,GASPRSCRO,COUNTRY,JPN,YEAR,WPR,Western Pacific,NA,2016,NA,NA,NA,NA,NA,NA,NA,20.87,20.86514,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Japan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7792111,GASPRSCRO,COUNTRY,AUT,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Austria,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9515244,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7900970,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9589988,GASPRSCRO,COUNTRY,GRC,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Greece,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9642819,GASPRSCRO,COUNTRY,ITA,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Italy,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9648856,GASPRSCRO,COUNTRY,BRA,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Brazil,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9654149,GASPRSCRO,COUNTRY,MYS,YEAR,WPR,Western Pacific,NA,2017,NA,NA,NA,NA,NA,NA,NA,5.8,5.7971,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Malaysia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9693102,GASPRSCRO,COUNTRY,SGP,YEAR,WPR,Western Pacific,NA,2011,NA,NA,NA,NA,NA,NA,NA,6.88,6.875,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Singapore,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9732230,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9764017,GASPRSCRO,COUNTRY,MDG,YEAR,AFR,Africa,NA,2018,NA,NA,NA,NA,NA,NA,NA,1.23,1.23457,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Madagascar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9787271,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9813716,GASPRSCRO,COUNTRY,NOR,YEAR,EUR,Europe,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Norway,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9818878,GASPRSCRO,COUNTRY,COL,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Colombia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9819288,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2013,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9846568,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2015,NA,NA,NA,NA,NA,NA,NA,2.83,2.83019,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9864559,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2011,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2011,2011-01-01T00:00:00+01:00,2011-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9877592,GASPRSCRO,COUNTRY,SWE,YEAR,EUR,Europe,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Sweden,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9884081,GASPRSCRO,COUNTRY,FIN,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Finland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7976907,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9910121,GASPRSCRO,COUNTRY,PRY,YEAR,AMR,Americas,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Paraguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10027573,GASPRSCRO,COUNTRY,IRL,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10084668,GASPRSCRO,COUNTRY,CYP,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Cyprus,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8042109,GASPRSCRO,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Qatar,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8217034,GASPRSCRO,COUNTRY,PER,YEAR,AMR,Americas,NA,2016,NA,NA,NA,NA,NA,NA,NA,2.38,2.38095,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Peru,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8276054,GASPRSCRO,COUNTRY,URY,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Uruguay,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8281536,GASPRSCRO,COUNTRY,ESP,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Spain,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9894601,GASPRSCRO,COUNTRY,BEL,YEAR,EUR,Europe,NA,2012,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2012,2012-01-01T00:00:00+01:00,2012-12-31T00:00:00+01:00,Belgium,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7941262,GASPRSCRO,COUNTRY,KOR,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,47.54,47.54098,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Republic of Korea,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
7964956,GASPRSCRO,COUNTRY,BOL,YEAR,AMR,Americas,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Bolivia (Plurinational State of),Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10141705,GASPRSCRO,COUNTRY,BTN,YEAR,SEAR,South-East Asia,NA,2016,NA,NA,NA,NA,NA,NA,NA,1.28,1.27796,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,Bhutan,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8032795,GASPRSCRO,COUNTRY,THA,YEAR,SEAR,South-East Asia,NA,2009,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,Thailand,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
10142258,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2016,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2016,2016-01-01T00:00:00+01:00,2016-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8157211,GASPRSCRO,COUNTRY,LKA,YEAR,SEAR,South-East Asia,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Sri Lanka,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9504452,GASPRSCRO,COUNTRY,PHL,YEAR,WPR,Western Pacific,NA,2014,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2014,2014-01-01T00:00:00+01:00,2014-12-31T00:00:00+01:00,Philippines,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8269210,GASPRSCRO,COUNTRY,GBR,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8293837,GASPRSCRO,COUNTRY,MLT,YEAR,EUR,Europe,NA,2017,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2017,2017-01-01T00:00:00+01:00,2017-12-31T00:00:00+01:00,Malta,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8456736,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2010,NA,NA,NA,NA,NA,NA,NA,3.92,3.92157,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8510467,GASPRSCRO,COUNTRY,IND,YEAR,SEAR,South-East Asia,NA,2009,NA,NA,NA,NA,NA,NA,NA,10.81,10.81081,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2009,2009-01-01T00:00:00+01:00,2009-12-31T00:00:00+01:00,India,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8783086,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2015,NA,NA,NA,NA,NA,NA,NA,0.06,0.05544,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8881130,GASPRSCRO,COUNTRY,ARE,YEAR,EMR,Eastern Mediterranean,NA,2020,NA,NA,NA,NA,NA,NA,NA,1.8,1.8,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,United Arab Emirates,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
8996238,GASPRSCRO,COUNTRY,LVA,YEAR,EUR,Europe,NA,2010,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Latvia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9018016,GASPRSCRO,COUNTRY,AUS,YEAR,WPR,Western Pacific,NA,2013,NA,NA,NA,NA,NA,NA,NA,0.57,0.57178,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2013,2013-01-01T00:00:00+01:00,2013-12-31T00:00:00+01:00,Australia,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9048749,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2015,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2015,2015-01-01T00:00:00+01:00,2015-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9182269,GASPRSCRO,COUNTRY,DNK,YEAR,EUR,Europe,NA,2020,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2020,2020-01-01T00:00:00+01:00,2020-12-31T00:00:00+01:00,Denmark,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9293682,GASPRSCRO,COUNTRY,USA,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0.17,0.17442,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,United States of America,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9331825,GASPRSCRO,COUNTRY,FJI,YEAR,WPR,Western Pacific,NA,2010,NA,NA,NA,NA,NA,NA,NA,0.37,0.36969,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2010,2010-01-01T00:00:00+01:00,2010-12-31T00:00:00+01:00,Fiji,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
9572579,GASPRSCRO,COUNTRY,PER,YEAR,AMR,Americas,NA,2018,NA,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-02-09T17:56:38.923+01:00,2018,2018-01-01T00:00:00+01:00,2018-12-31T00:00:00+01:00,Peru,Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP,EN,NA
